research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
Search
for
Sort by
Research
240-270 / 1000+ results
research The BJUI 's clinical trials initiative
The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
research Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial
Topical treatment SM04554 safely promotes hair growth in male baldness.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome
Parents of women with PCOS have a higher risk of Type II diabetes and insulin resistance, especially fathers.
research Idiopathic CD4+ T-lymphocytopenia
ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.
research Overexpression of human keratin 16 produces a distinct skin phenotype in transgenic mouse skin
High levels of human keratin 16 in mice cause skin lesions and abnormal skin development.
research Characterization of Novel Cutaneous Human Papillomavirus Genotypes HPV-150 and HPV-151
HPV-150 and HPV-151 are rare skin viruses linked to warts and some skin cancers.
research Two Cases of Hypertrichosis Cubiti
Two cases of hairy elbows syndrome were described, with normal skin texture and symmetrical hair growth.
research 555 Dermal single-cell atlas: a novel tool to explore fibroblast heterogeneity
A new tool helps study hair follicle cells to develop better treatments for hair disorders.
research Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future
Hair regrowth improved, but quality of life did not.
research The difficulty of finding ‘healthy’ volunteers
Most people who volunteered for a health study had medical issues, showing the need for careful screening before trials.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research BH06: Clinical trial of combination therapy with oral hydroxychloroquine and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research 40753 Trends in ethnoracial representation in alopecia areata clinical trials: a cross-sectional study
Hispanic and Black patients are underrepresented in alopecia areata clinical trials.
research Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
Abrocitinib may help treat alopecia areata effectively with mild side effects.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
research Alopecia areata clinical trial enrollment and retention outcome factors among underrepresented ethnic and racial groups: A cross-sectional study
Clinical trials for alopecia areata need better inclusion and retention of patients of color.
research Blinding in Placebo-Controlled Trials
The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.